Investment
Features
FeesSafety
Academy
More
Pluang+

Compare National Beverage Corp. (FIZZ) vs 10X Genomics Inc (TXG) Price & Performance

National Beverage Corp.Trade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

National Beverage Corp. vs 10X Genomics Inc — how do they compare? National Beverage Corp. trades at $30.27 (market cap $2.89B), while 10X Genomics Inc trades at $81.58 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 3.5× National Beverage Corp.'s market cap, and 10X Genomics Inc is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and 10X Genomics Inc for 92 Days on average.

FIZZTXG
Market Cap
$2.89B$10.07B
Volume
553,9505,657,286
Sector
Consumer StaplesHealth
52-Week High
$37.73$97.74
52-Week Low
$29.20$11.48
Typical Hold Time
33 Days92 Days
Enterprise Value
$2.84B$9.59B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

National Beverage Corp.

FIZZ trades at $30.58, up 3.31% today, but faces bearish technical signals with recent earnings misses. Revenue has stagnated around $1.2B annually, though net income margins improved to 15.55% in 2025. The company maintains strong profitability with 40.13% ROE but faces margin pressure from input costs. A $3.25 special dividend payment in July 2026 reduced shareholder equity significantly.

Outlook remains challenging with analyst consensus leaning bearish (50% sell ratings). While valuation appears reasonable (P/E 16.58), stagnant growth and consecutive earnings misses pose headwinds. The key opportunity lies in potential revenue recovery, but investors face risks from competitive pressures and ongoing margin compression.

10X Genomics Inc

TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.

The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FIZZ

No sentiment data available yet.

TXG
4% Buy96% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About National Beverage Corp.

National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.

Read more on FIZZ →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →